The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.i

Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

Common (5-17%). Occasionally severe mimicking/overlapping with anaphylaxis (1%) (PMID 12818276)

Publications

Yun H, Xie F, Beyl RN, Chen L, Lewis JD, Saag KG, Curtis JR

Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis.

Arthritis care & research 2017 10;69;1526-1534 — 2017 10 — 1526-1534

Aeschlimann FA, Hofer KD, Cannizzaro Schneider E, Schroeder S, Lauener R, Saurenmann RK

Infliximab in pediatric rheumatology patients: a retrospective analysis of infusion reactions and severe adverse events during 2246 infusions over 12 years.

The Journal of rheumatology 2014 Jul;41;1409-15 — 2014 Jul — 1409-15

Hamzaoglu H, Cooper J, Alsahli M, Falchuk KR, Peppercorn MA, Farrell RJ

Safety of infliximab in Crohn's disease: a large single-center experience.

Inflammatory bowel diseases 2010 Dec;16;2109-16 — 2010 Dec — 2109-16